The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment: A Systematic Review and Meta-Analysis
Abstract
Clinicians have long sought to characterize biological markers of neoplasia as objective indicators of tumor presence, pathogenicity, and prognosis. Armed with data that correlate biomarker activity with disease presence and progression, clinicians can develop treatment strategies that address risks of disease recurrence or persistence and progression. The B-type Raf kinase (BRAF V600E) mutation in exon 15 of the BRAF gene has been noted to be a putative prognostic marker of the most prevalent form of thyroid cancer, papillary thyroid cancer (PTC)--a tumor type with high proclivity for recurrence or persistence. There has been a remarkable interest in determining the association of BRAF mutation with PTC recurrence or persistence. Using many new studies that have been published recently, we performed a meta-analysis to investigate correlations of BRAF mutation status with PTC prognosis, focusing on the recurrence or persistence of the disease after initial treatment. The study was based on published studies included in the PubMed and Embase databases addressing the BRAF mutation and the frequency of recurrence of PTC. We selected studies with data that enabled measurement of the risk ratio for recurrent disease. We also analyzed the factors that are classically known to be associated with recurrence. These factors included lymph node metastasis, extrathyroidal extension, distant metastasis, and American Joint Committee on Cancer (AJCC) stages III/IV. We used 14 articles that included an analysis of these factors as well as PTC recurrence data, with a total of 2470 patients from 9 different countries. The overall prevalence of the BRAF mutation was 45%. The risk ratios in BRAF mutation-positive patients were 1.93 (95% confidence interval [CI], 1.61-2.32; Z = 7.01; p < 0.00001) for PTC recurrence, 1.32 (95% CI, 1.20-1.45; Z = 5.73; p < 0.00001) for lymph node metastasis, 1.71 (95% CI, 1.50-1.94; Z = 8.09; p < 0.00001) for extrathyroidal extension, 0.95 (95% CI, 0.63-1.44; Z = 0.23; p = 0.82) for distant metastasis, and 1.70 (95% CI, 1.45-1.99; Z = 6.46; p < 0.00001) for advanced stage AJCC III/IV. Thus, in this meta-analysis, the BRAF mutation in PTC was significantly associated with PTC recurrence, lymph node metastasis, extrathyroidal extension, and advanced stage AJCC III/IV. Patients with PTC harboring mutated BRAF are likely to demonstrate factors that are associated with an increased risk for recurrence of the disease, offering new prospects for optimizing and tailoring initial treatment strategies to prevent recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,369
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Mazzaferri, E. L., & Jhiang, S. M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90321-2 · Cited by 2,635
Hundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Self-citationNikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,042
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Self-citationXing, M. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0007 · Cited by 983
Self-citationBRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
Self-citationGarnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
Soares, P., Trovisco, V., Rocha, A. S., Lima, J., Castro, P., Preto, A., Máximo, V., Botelho, T., Seruca, R., & Sobrinho-Simões, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206706 · Cited by 679
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030305 · Cited by 533
Elisei, R., Ugolini, C., Viola, D., Lupi, C., Biagini, A., Giannini, R., Romei, C., Miccoli, P., Pinchera, A., & Basolo, F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0607 · Cited by 528
Adeniran, A. J., Zhu, Z., Gandhi, M., Steward, D. L., Fidler, J. P., Giordano, T. J., Biddinger, P. W., & Nikiforov, Y. E. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000176432.73455.1b · Cited by 495
The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer
Kebebew, E., Weng, J., Bauer, J., Ranvier, G., Clark, O. H., Duh, Q.-Y., Shibru, D., Bastian, B., & Griffin, A. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e318148563d · Cited by 480
Zaydfudim, V., Feurer, I. D., Griffin, M. R., & Phay, J. E. (2008) · Surgery · doi:10.1016/j.surg.2008.08.034 · Cited by 453
High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu, X., Quiros, R. M., Gattuso, P., Ain, K. B., & Prinz, R. A. (2003) · PubMed · Cited by 415
Kim, T. H., Park, Y. J., Lim, J. A., Ahn, H. Y., Lee, E. K., Lee, Y. J., Kim, K. W., Hahn, S. K., Youn, Y. K., Kim, K. H., et al. (2012) · Cancer · doi:10.1002/cncr.26500 · Cited by 400
BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism
Durante, C., Puxeddu, E., Ferretti, E., Morisi, R., Moretti, S., Bruno, R., Barbi, F., Avenia, N., Scipioni, A., Verrienti, A., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2707 · Cited by 397
Riesco-Eizaguirre, G., Gutiérrez-Martínez, P., García-Cabezas, M. A., Nistal, M., & Santisteban, P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01119 · Cited by 376
Hwang, H. S., & Orloff, L. A. (2011) · The Laryngoscope · doi:10.1002/lary.21227 · Cited by 336
Griffith, O. L., Melck, A., Jones, S. J. M., & Wiseman, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7330 · Cited by 314
Lee, J., Lee, E., & Kim, Y. (2007) · Cancer · doi:10.1002/cncr.22754 · Cited by 291
ITO, Y., YOSHIDA, H., MARUO, R., MORITA, S., TAKANO, T., HIROKAWA, M., YABUTA, T., FUKUSHIMA, M., INOUE, H., TOMODA, C., et al. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-208 · Cited by 255
Ohori, N. P., Nikiforova, M. N., Schoedel, K. E., LeBeau, S. O., Hodak, S. P., Seethala, R. R., Carty, S. E., Ogilvie, J. B., Yip, L., & Nikiforov, Y. E. (2010) · Cancer Cytopathology · doi:10.1002/cncy.20063 · Cited by 254
Kloos, R. T., & Mazzaferri, E. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0492 · Cited by 252
Kim, T. Y., Kim, W. B., Rhee, Y. S., Song, J. Y., Kim, J. M., Gong, G., Lee, S., Kim, S. Y., Kim, S. C., Hong, S. J., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02605.x · Cited by 238
Fugazzola, L., Puxeddu, E., Avenia, N., Romei, C., Cirello, V, Cavaliere, A., Faviana, P., Mannavola, D., Moretti, S., Rossi, S., et al. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01086 · Cited by 237
Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population
Kim, K. H., Kang, D. W., Kim, S. H., Seong, I. O., & Kang, D. Y. (2004) · Yonsei Medical Journal · doi:10.3349/ymj.2004.45.5.818 · Cited by 229
Kim, T. Y., Kim, W. B., Song, J. Y., Rhee, Y. S., Gong, G., Cho, Y. M., Kim, S. Y., Kim, S. C., Hong, S. J., & Shong, Y. K. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02389.x · Cited by 221
Association of High Iodine Intake with the T1799A BRAF Mutation in Papillary Thyroid Cancer
Guan, H., Ji, M., Bao, R., Yu, H., Wang, Y., Hou, P., Zhang, Y., Shan, Z., Teng, W., & Xing, M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2390 · Cited by 218
Self-citationPrognostic utility of BRAF mutation in papillary thyroid cancer
Xing, M. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.012 · Cited by 210
Self-citationLin, K.-L., Wang, O.-C., Zhang, X.-H., Dai, X.-X., Hu, X.-Q., & Qu, J.-M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1129-6 · Cited by 175
Abubaker, J., Jehan, Z., Bavi, P., Sultana, M., Al-Harbi, S., Ibrahim, M., Al-Nuaim, A., Ahmed, M., Amin, T., Al-Fehaily, M., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1717 · Cited by 169
Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation
Yip, L., Nikiforova, M. N., Carty, S. E., Yim, J. H., Stang, M. T., Tublin, M. J., LeBeau, S. O., Hodak, S. P., Ogilvie, J. B., & Nikiforov, Y. E. (2009) · Surgery · doi:10.1016/j.surg.2009.09.011 · Cited by 165
BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications
Tang, K., & Lee, C. (2010) · Journal of the Chinese Medical Association · doi:10.1016/s1726-4901(10)70025-3 · Cited by 164
Pyrosequencing Analysis for Detection of a BRAFV600E Mutation in an FNAB Specimen of Thyroid Nodules
Kim, S. K., Kim, D., Han, H. S., Kim, W. S., Kim, S. J., Moon, W., Oh, S. Y., & Hwang, T. S. (2008) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31815d059d · Cited by 146
Handkiewicz-Junak, D., Czarniecka, A., & Jarząb, B. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.01.007 · Cited by 132
High Rate of BRAF and RET/PTC Dual Mutations Associated with Recurrent Papillary Thyroid Carcinoma
Henderson, Y. C., Shellenberger, T. D., Williams, M. D., El‐Naggar, A. K., Fredrick, M. J., Cieply, K. M., & Clayman, G. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0933 · Cited by 132
Kwak, J. Y., Kim, E., Chung, W. Y., Moon, H. J., Kim, M. J., & Choi, J. R. (2009) · Radiology · doi:10.1148/radiol.2533090471 · Cited by 131
Costa, Â. M., Herrero, A., Fresno, M., Heymann, J. J., Alvarez, J. A., Cameselle‐Teijeiro, J., & García‐Rostán, G. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03077.x · Cited by 129
Oler, G., & Cerutti, J. M. (2009) · Cancer · doi:10.1002/cncr.24118 · Cited by 123
Sapio, M. R., Posca, D., Troncone, G., Pettinato, G., Palombini, L., Rossi, G., Fenzi, G., & Vitale, M. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02072 · Cited by 102
Oler, G., Camacho, C. P., Hojaij, F. C., Michaluart, P., Riggins, G. J., & Cerutti, J. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4372 · Cited by 102
Park, Y. J., Kim, Y. A., Lee, Y. J., Kim, S. H., Park, S. Y., Kim, K. W., Chung, J. K., Youn, Y., Kim, K. H., Park, D. J., et al. (2009) · Head & Neck · doi:10.1002/hed.21142 · Cited by 95
Contemporary management of papillary carcinoma of the thyroid gland
Rosenbaum, M. A., & McHenry, C. R. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.3.317 · Cited by 83
Lymphatic Mapping Establishes the Role of BRAF Gene Mutation in Papillary Thyroid Carcinoma
Kim, J., Giuliano, A. E., Turner, R. R., Gaffney, R., Umetani, N., Kitago, M., Elashoff, D. A., & Hoon, D. S. �. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000224751.80858.13 · Cited by 79
Recent Advances in Molecular Biology of Thyroid Cancer and Their Clinical Implications
Xing, M. (2008) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2008.07.001 · Cited by 77
Self-citationHowell, G. M., Carty, S. E., Armstrong, M. J., LeBeau, S. O., Hodak, S. P., Coyne, C., Stang, M. T., McCoy, K. L., Nikiforova, M. N., Nikiforov, Y. E., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1781-5 · Cited by 73
The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer
Melck, A. L., Yip, L., & Carty, S. E. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0156 · Cited by 67
Barollo, S., Pennelli, G., Vianello, F., Watutantrige‐Fernando, S., Negro, I., Boschin, I. M., Pelizzo, M. R., Rugge, M., Mantero, F., Nacamulli, D., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0290 · Cited by 65
IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer
Liu, Z., Liu, D., Bojdani, E., El‐Naggar, A. K., Vasko, V. V., & Xing, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1627 · Cited by 64
Self-citationClonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas
Wang, W., Wang, H., Teng, X., Wang, H., Mao, C., Teng, R., Zhao, W., Cao, J., Fahey, T. J., & Teng, L. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.02.008 · Cited by 63
Nakayama, H., Yoshida, A., Nakamura, Y., Hayashi, H., Miyagi, Y., Wada, N., Rino, Y., Masuda, M., & Imada, T. (2007) · PubMed · Cited by 63
Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer
Lundgren, C. I., Hall, P. N., Dickman, P. W., & Zedenius, J. (2007) · British journal of surgery · doi:10.1002/bjs.5635 · Cited by 58
Lassalle, S., Hofman, V., Ilié, M., Butori, C., Bozec, A., Santini, J., Vielh, P. R., & Hofman, P. M. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791111189 · Cited by 44
Sýkorová, V., Dvořáková, Š., Ryška, A., Včelák, J., Václavíková, E., Laco, J., Kodetova, D. N., Kodet, R., Cibula, A., Duskova, J., et al. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03346593 · Cited by 41
Identifying a risk profile for thyroid cancer
Ward, L. S., Morari, E. C., Leite, J. L., Búfalo, N. E., Guilhen, A. C. T., de Araujo, P. P. C., Tincani, Á. J., da Assumpção, L. V. M., & Matos, P. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000500008 · Cited by 26
Considerations for Personalized Surgery in Patients with Papillary Thyroid Cancer
Tufano, R. P., & Kandil, E. H. (2010) · Thyroid · doi:10.1089/thy.2010.1645 · Cited by 24
Self-citationPark, S., Kim, H., Hah, J. H., Kim, K., Heo, D., & Sung, M. (2010) · Head & Neck · doi:10.1002/hed.21362 · Cited by 23
Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma
Musholt, T. J., Schönefeld, S., Schwarz, C. H., Watzka, F., Musholt, P. B., Fottner, C., Weber, M. M., Springer, E., & Schad, A. (2010) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-010-0682-6 · Cited by 22
Pathogenesis of differentiated thyroid cancer (papillary and follicular)
Maciel, R. M. B., Kimura, E. T., & Cerutti, J. M. (2005) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302005000500009 · Cited by 13
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Xing, M., Liu, R., Liu, X., Murugan, A. K., Zhu, G., Zeiger, M. A., Pai, S., & Bishop, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5094 · Cited by 725
Self-citationPatel, K. N., Yip, L., Lubitz, C. C., Grubbs, E. G., Miller, B. S., Shen, W., Angelos, P., Chen, H., Doherty, G. M., Fahey, T. J., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003580 · Cited by 541
Self-citationJung, C. K., Little, M. P., Lubin, J. H., Brenner, A. V., Wells, S. A., Sigurdson, A. J., & Nikiforov, Y. E. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2503 · Cited by 343
Liu, R., Bishop, J., Zhu, G., Zhang, T., Ladenson, P. W., & Xing, M. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3288 · Cited by 296
Self-citation
Metadata
- Authors
- Tufano, R. P., Teixeira, G. V., Bishop, J., Carson, K. A., & Xing, M.
- Venue
- Medicine
- Published
- 2012-09
- Volume
- 91
- Issue
- 5
- Pages
- 274-286
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2163455037
- Cited by
- 302
- References
- 63
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.